Trial Profile
A Retrospective trial of 90Y-Ibritumomab Tiuxetan after Autologous Stem Cell Transplantation in Intermediate/High-Risk Diffuse Large B-Cell Lymphoma Patients not Responding Adequately
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Dec 2015
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 26 Dec 2015 New trial record